<DOC>
	<DOC>NCT00557323</DOC>
	<brief_summary>Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum carbonate (Fosrenol), for an additional 5 years. Patients were being observed for any bone adverse events or other serious adverse events, as well as the collection of mortality data.</brief_summary>
	<brief_title>Long-term Effect of Lanthanum Carbonate on Bone</brief_title>
	<detailed_description />
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Any patient who had exposure to lanthanum carbonate in SPD405309</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>